ArticlePregnancy (Hoboken, N.J.)2026
Hypertension-related morbidity after delivery discharge: A comparison of nifedipine versus labetalol.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate rates of hypertension-related morbidity after delivery discharge among individuals on nifedipine versus labetalol monotherapy. Methods: This was a retrospective cohort study of individuals who delivered at a level IV obstetric hospital from January 1, 2021 to January 20, 2024, had a hypertensive disorder of pregnancy, and were discharged on nifedipine or labetalol monotherapy. The primary outcome was hypertension-related post-discharge morbidity, defined as any of the following within 30 days of delivery discharge: severe hypertension, de novo preeclampsia lab abnormalities, or new-onset clinical morbidity (hemolysis, elevated liver enzymes and low platelets [HELLP] syndrome, eclampsia, pulmonary edema/acute heart failure, cerebrovascular disorders, myocardial infarction/cardiac arrest, liver hematoma, or acute renal failure). Secondary outcomes included hypertension-related hospital return and hospital return length of stay. Data were abstracted from the medical record. Logistic regression and bivariate analysis were used to compare groups. Multivariable logistic regression was used to adjust for baseline characteristics and readmission risk factors from the literature. Results: Of 360 patients meeting inclusion criteria, 67.2% were discharged on nifedipine and 32.8% were discharged on labetalol. Nifedipine recipients had lower body mass index and were less likely to have chronic hypertension compared to labetalol recipients. Post-discharge morbidity occurred less frequently among individuals discharged on nifedipine compared to labetalol (1.7% vs. 10.2%; adjusted odds ratio [aOR], 0.1; 95% confidence interval [CI], 0.05-0.5). Individuals on nifedipine were less likely to return to the hospital in the 30 days following discharge (4.6% vs. 12.7%; aOR, 0.3; 95% CI, 0.1-0.7) and less likely to have a hospital return lasting ≥24 h (1.7% vs. 6.8%; OR, 0.2; 95% CI, 0.07-0.8). Conclusion: Among individuals on antihypertensive monotherapy at delivery discharge, nifedipine was associated with significantly reduced odds of post-discharge morbidity compared to labetalol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.